



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

1 April 2020
EMA/646339/2019
Press office

Recommendations on eligibility to PRIME scheme

Adopted at the CHMP meeting of 23-26 March 2020

During its March 2020 meeting, the CHMP reviewed 2 recommendations for eligibility to PRIME: 2 were denied. The individual outcomes adopted this month are listed below.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union




Eligibility denied

Substance type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Immunological	Infectious Diseases	Prevention of dengue disease in individuals 1 year of age and older, at risk of exposure by living in or traveling to dengue endemic areas	Nonclinical+ Clinical exploratory	Other
Advanced Therapy	Uro-nephrology	Treatment of chronic kidney disease/diabetic kidney disease	Nonclinical+ Clinical exploratory	Other

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other type of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.


Cumulative overview of recommendations on PRIME eligibility requests adopted by 26 March 2020

N= 288



■ Granted ■ Denied ■ Out of scope* ■ Withdrawn

By therapeutic area



By type of applicant



■ Granted ■ Denied

* This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area.